Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: A meta-analysis

Aging Male

Volumn 18, Issue 4, 2015, Pages 233-237

  Dong, ZhiLong ^a   Wang, Hanzhang ^b   Xu, MengMeng ^c   Li, Yang ^a   Hou, MingLi ^d   Wei, YanLing ^a   Liu, Xingchen ^a   Wang, ZhiPing ^a   Xie, XiaoDong ^a  

^a LANZHOU UNIVERSITY   (China)

^b TULANE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Hormone therapy; meta analysis; prostate cancer

Indexed keywords

ADVANCED CANCER; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CONSTIPATION; CONTINUOUS HORMONE THERAPY; DEPRESSION; DISEASE COURSE; FOLLOW UP; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; INTERMITTENT HORMONE THERAPY; MALE; META ANALYSIS; PENIS DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; HORMONE SUBSTITUTION; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

TESTOSTERONE;

DRUG ADMINISTRATION SCHEDULE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TESTOSTERONE;

EID: 84948711839     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2015.1065245     Document Type: Article

References (19)

1. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166
2. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107
3. Ye D, Yao Z. Epidemiological trends of prostate cancer in China. Chin Clin Oncol 2007; 11: 616-21
4. Noble RL. Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants. Oncology 1977; 34: 138-41
5. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 1996; 58: 139-46
6. Langenhuijsen JF, van Lin EN, Hoffmann AL, et al. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol Semin Orig Investig 2011; 29: 52-7
7. de Leval J, Boca P, Youssef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1: 163-71
8. da Silva FECC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-77
9. Mottet N, Goussard M, Loulidi S, et al. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial. Eur Urol Suppl 2009; 8: 131
10. Salonen AJ, Taari KO, Ala-Opas MY, et al. Finnprostate study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. Eur Urol Suppl 2012; 11: 131
11. Crook JM, Szumacher E, Malone S, et al. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 530-4
12. Grossfeld GD, Chaudhary UB, Reese DM, et al. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001; 58: 240-5
13. Bouchot O, Lenormand L, Karam G, et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
14. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82
15. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-25
16. Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987; 137: 785-8
17. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer 1993; 71: 2782-90
18. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007; 99: 1056-65
19. Seruga B, Tannock F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5: 574-6